Guilford Pharmaceuticals to Announce Second Quarter 2005 Financial Results on Monday, August 8, 2005

BALTIMORE, Aug. 2  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) will host a conference call and live audio webcast to announce its second quarter 2005 financial results on Monday, August 8, 2005, beginning at 4:00 p.m. E.T.  During this call, Guilford's management will discuss the financial results and other business for the upcoming year.

The press release and live webcast can be accessed by going to the Investor Relations section of Guilford's website at http://www.guilfordpharm.com/.  Following the webcast, an archived version of the call will be available until Monday, August 22, 2005.

To participate in the live conference call, U.S. residents should dial 866-700-6067, international callers 617-213-8834.  The participant passcode is 10862875.

An audio replay of the conference call will be available for 48 hours beginning at approximately 6:00 p.m. E.T. on August 8, 2005 through 6:00 p.m. August 10, 2005.  To access the replay, U.S. residents should dial 888-286-8010, (int'l callers 617-801-6888), passcode 80343638.

Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market.  Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS).  Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction.

   Contact:  Guilford Pharmaceuticals Inc.
             Stacey Jurchison 410.631.5022
             

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Guilford Pharmaceuticals Inc.,

[phone], 



Web site:  http://www.guilfordpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright